SLC1A5 and ovarian carcinoma: Studies have shown that the combined detection of ASCT2 and p-mTOR can be used as a molecular marker for ovarian cancer, providing reference information for the diagnosis, postoperative follow-up, and targeted therapy of early ovarian cancer patients (44).